PREVENT Cancer Preclinical Drug Development Program (PREVENT)

Image of a scientist preparing genetic samples.

The PREVENT program supports the preclinical development of innovative cancer prevention interventions and biomarkers toward clinical applications. PREVENT uses NCI contract resources and expertise, instead of direct funding, to generate data and materials needed for agent development. The program is a peer-reviewed pipeline focused on unmet research needs that are not adequately addressed by the private sector. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Read more About PREVENT.

Application Instructions

Submission deadlines occur twice per year on the first Monday in February and September.

NEXT Deadline: February 3, 2020

Instructions for Applying
Please use the latest application template. (DOC, 31 KB)

Supported Projects

95 Projects from PREVENT Cycles 1 through 16: 

  • 59 chemoprevention projects
  • 28 immunoprevention projects
  • 8 biomarker projects

Read more about supported projects and supported prevention approaches.

Available Resources

  • Efficacy and Intermediate Endpoint Biomarker Work
  • Toxicology and Pharmacology Testing
  • CGMP Production of Vaccines and Biologicals
  • Prime Contractors 2019–2023

View available resources

Program Administration

  • Governance Structure
  • Intellectual Property Considerations
  • Data Access

Learn more about program administration